Infinity Pharmaceuticals (INFIQ) Stock Price
Infinity Pharmaceuticals Price
Revenue at Infinity Pharmaceuticals has contracted by 14.0% per year over the past 19 years to 2.59 M USD. Infinity Pharmaceuticals's net margin stands at -1,711.1%, down from -51.1% several years earlier.
Infinity Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Infinity Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Infinity Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Infinity Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Infinity Pharmaceuticals Price |
|---|---|
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
| 7/21/2026 | 0.00 USD |
| 7/20/2026 | 0.00 USD |
| 7/17/2026 | 0.00 USD |
| 7/16/2026 | 0.00 USD |
| 7/15/2026 | 0.00 USD |
| 7/14/2026 | 0.00 USD |
| 7/13/2026 | 0.00 USD |
| 7/10/2026 | 0.00 USD |
| 7/9/2026 | 0.00 USD |
| 7/8/2026 | 0.00 USD |
| 7/7/2026 | 0.00 USD |
| 7/6/2026 | 0.00 USD |
| 7/2/2026 | 0.00 USD |
| 7/1/2026 | 0.00 USD |
| 6/30/2026 | 0.00 USD |
| 6/29/2026 | 0.00 USD |
| 6/26/2026 | 0.00 USD |
| 6/25/2026 | 0.00 USD |
| 6/24/2026 | 0.00 USD |
| 6/23/2026 | 0.00 USD |
| 6/22/2026 | 0.00 USD |
| 6/18/2026 | 0.00 USD |
| 6/17/2026 | 0.00 USD |
| 6/16/2026 | 0.00 USD |
| 6/12/2026 | 0.00 USD |
| 6/11/2026 | 0.00 USD |
| 6/10/2026 | 0.00 USD |
| 6/9/2026 | 0.00 USD |
| 6/8/2026 | 0.00 USD |
| 6/5/2026 | 0.00 USD |
| 6/4/2026 | 0.00 USD |
| 6/3/2026 | 0.00 USD |
| 6/2/2026 | 0.00 USD |
| 6/1/2026 | 0.00 USD |
| 5/29/2026 | 0.00 USD |
| 5/28/2026 | 0.00 USD |
| 5/27/2026 | 0.00 USD |
| 5/26/2026 | 0.00 USD |
| 5/22/2026 | 0.00 USD |
| 5/21/2026 | 0.00 USD |
| 5/20/2026 | 0.00 USD |
| 5/19/2026 | 0.00 USD |
| 5/18/2026 | 0.00 USD |
| 5/15/2026 | 0.00 USD |
| 5/14/2026 | 0.00 USD |
| 5/13/2026 | 0.00 USD |
| 5/12/2026 | 0.00 USD |
| 5/11/2026 | 0.00 USD |
| 5/8/2026 | 0.00 USD |
| 5/7/2026 | 0.00 USD |
| 5/6/2026 | 0.00 USD |
| 5/5/2026 | 0.00 USD |
| 11/20/2025 | 0.00 USD |
| 10/10/2025 | 0.00 USD |
| 10/2/2025 | 0.00 USD |
| 9/19/2025 | 0.00 USD |
Infinity Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Infinity Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 165.00 | 109.00 | 18.00 | 6.00 | 22.00 | 3.00 | 1.00 | 1.00 | 2.00 | – | – | 2.00 | 18.00 | 55.00 | 87.00 |
| – | – | -33.94 | -83.49 | -66.67 | 266.67 | -86.36 | -66.67 | – | 100.00 | – | – | – | 800.00 | 205.56 | 58.18 |
| – | 0.61 | 0.92 | 5.56 | 16.67 | 100.00 | -133.33 | 100.00 | 100.00 | 50.00 | – | – | 50.00 | 50.00 | 50.00 | 50.00 |
| 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 22.00 | -4.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 9.00 | 27.50 | 43.50 |
| -127.00 | -7.00 | -127.00 | -143.00 | -36.00 | -11.00 | -44.00 | -38.00 | -45.00 | -44.00 | -49.00 | -43.00 | -2.00 | -18.00 | -55.00 | – |
| – | -4.24 | -116.51 | -794.44 | -600.00 | -50.00 | -1,466.67 | -3,800.00 | -4,500.00 | -2,200.00 | – | – | -100.00 | -100.00 | -100.00 | – |
| -126.00 | -17.00 | -128.00 | -30.00 | -41.00 | -11.00 | -47.00 | -40.00 | -45.00 | -44.00 | – | – | -25.00 | -11.00 | 8.00 | – |
| 133.33 | -86.51 | 652.94 | -76.56 | 36.67 | -73.17 | 327.27 | -14.89 | 12.50 | -2.22 | – | – | – | -56.00 | -172.73 | – |
| 47.90 | 48.60 | 49.10 | 49.60 | 50.60 | 55.40 | 57.00 | 60.00 | 86.00 | 89.39 | 89.39 | 89.39 | 89.39 | 89.39 | 89.39 | 89.39 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Infinity Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Infinity Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Infinity Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Infinity Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Infinity Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Infinity Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Infinity Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Infinity Pharmaceuticals business model & stock analysis
Infinity Pharmaceuticals SWOT Analysis
Strengths
Infinity Pharmaceuticals Inc possesses several strengths that contribute to its success and competitive advantage in the industry. These strengths include:
Infinity Pharmaceuticals Inc has a well-established research and development (R&D) department, which allows them to continuously innovate and develop new drugs and therapies. This helps in staying ahead of competitors and meeting the changing needs of the market.
The company has a diverse and promising drug pipeline, with several potential candidates in various stages of development. This provides them with the opportunity to secure future revenue streams and expand their product portfolio.
Infinity Pharmaceuticals Inc has established strategic partnerships with leading pharmaceutical companies, allowing them to leverage the resources, expertise, and distribution networks of their partners. These collaborations enhance their market presence and facilitate the commercialization of their drugs.
Weaknesses
Despite its strengths, Infinity Pharmaceuticals Inc also faces certain weaknesses that pose challenges to its growth and sustainability. These weaknesses include:
The company may face constraints in terms of financial resources and funding, which could impact their ability to fully capitalize on research opportunities, expand operations, or effectively compete with larger pharmaceutical companies.
Infinity Pharmaceuticals Inc's revenue stream heavily relies on a few key products. Any setbacks in the development, approval, or commercial success of these products can significantly impact the company's financial performance.
Opportunities
Infinity Pharmaceuticals Inc can capitalize on various opportunities to further enhance its market position and achieve sustained growth. These opportunities include:
As the healthcare industry evolves, there is an increasing demand for innovative therapies and personalized medicine. Infinity Pharmaceuticals Inc can leverage its strong R&D capabilities to develop and commercialize novel treatments that address unmet medical needs.
The company can explore additional strategic partnerships and collaborations to access new markets, technologies, or research expertise. Such alliances can enable them to accelerate drug development, increase market reach, and diversify their product offerings.
Threats
Infinity Pharmaceuticals Inc faces certain threats that could hinder its growth and profitability. These threats include:
The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Infinity Pharmaceuticals Inc faces competition from both established pharmaceutical companies and emerging biotech firms, which may affect their market penetration and pricing power.
Developing and commercializing pharmaceutical products involves navigating complex regulatory processes and receiving necessary approvals. Any delays or regulatory hurdles can impact product launches and revenue generation for Infinity Pharmaceuticals Inc.
Infinity Pharmaceuticals Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Infinity Pharmaceuticals Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Infinity Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Infinity Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Infinity Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Infinity Pharmaceuticals stock splits
Infinity Pharmaceuticals Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 2/24/2023 | Downgrade | OverweightNeutral | 51 | |
| 11/16/2022 | Downgrade | BuyNeutral | – | |
| 5/23/2022 | Maintained | Overweight | 51 | |
| 3/31/2022 | Maintained | Buy | – | |
| 3/30/2022 | Maintained | Overweight | 51 | |
| 8/2/2021 | Upgrade | NeutralOverweight | 80 | |
| 7/28/2021 | Upgrade | Equal WeightOverweight | 56 | |
| 3/17/2021 | Maintained | Equal Weight | 56 | |
| 2/5/2021 | Upgrade | UnderweightNeutral | 80 | |
| 5/18/2020 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Infinity Pharmaceuticals Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 3/26/2024 | -0.12USD | - | 772,500.00USD | - | 2023 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Infinity Pharmaceuticals stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Infinity Pharmaceuticals shareholder structure
| % | Name |
|---|---|
0.00000% |
Infinity Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
11.00% | SEC ↗ | |
10.20% | SEC ↗ | |
10.20% | SEC ↗ | |
7.50% | SEC ↗ | |
7.10% | SEC ↗ | |
7.10% | SEC ↗ | |
7.10% | SEC ↗ |
Infinity Pharmaceuticals Executives and Management Board
5 members · avg. age 69 · 0 % women
Mr. Seth Tasker (45)
Chief Executive Officer
1.44 M USD
Mr. Norman Selby (71)
Lead Independent Director
Dr. Anthony Evnin (82)
Independent Director
Mr. David Beier (74)
Independent Director
Dr. Richard Gaynor (75)
Independent Director
Frequently asked questions about Infinity Pharmaceuticals
The business model of Infinity Pharmaceuticals Inc is focused on developing and commercializing innovative medicines for the treatment of cancer. The company primarily focuses on discovering and developing small molecule drugs that target the inhibition of specific proteins involved in cancer growth and progression. Infinity Pharmaceuticals Inc adopts a research-driven approach to identify and advance potential drug candidates, leveraging its expertise in medicinal chemistry and biology. By collaborating with partners and conducting clinical trials, the company aims to bring novel therapies to patients with unmet medical needs in the oncology field.
Infinity Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
Infinity Pharmaceuticals Inc faces competition from several companies in the market. Some key competitors include Novartis AG, Pfizer Inc, Bristol-Myers Squibb Company, and Merck & Co., Inc. These competitors operate in the same industry and may have similar products or services to offer. However, Infinity Pharmaceuticals Inc has its unique strengths and strategies that set it apart from its competitors. It is essential for investors and stakeholders to keep an eye on the competitive landscape to assess Infinity Pharmaceuticals Inc's market position and potential.
Infinity Pharmaceuticals Inc is a renowned biopharmaceutical company with a rich history and background. Established in 2001, Infinity Pharmaceuticals has been dedicated to discovering, developing, and delivering innovative medicines for patients in need. Over the years, the company has consistently made significant contributions in the field of oncology, particularly in targeted therapies. With a focus on precision medicine, Infinity Pharmaceuticals utilizes advanced research and development techniques to identify and exploit key biological pathways involved in cancer growth. By leveraging its expertise, the company strives to improve patient outcomes and enhance the quality of life for individuals affected by cancer.
Infinity Pharmaceuticals Inc. has achieved several significant milestones. Firstly, the company successfully developed IPI-549, a potentially groundbreaking treatment for cancer. They also secured a collaboration agreement with Roche to evaluate IPI-549 in combination with Roche's cancer immunotherapy drugs. Furthermore, Infinity Pharmaceuticals Inc. initiated several clinical trials to assess the efficacy and safety of IPI-549 in patients with various types of cancer. These milestones demonstrate the company's dedication to advancing cancer treatments and establishing valuable partnerships within the industry. Infinity Pharmaceuticals Inc. continues to make strides in their mission to improve the lives of patients suffering from cancer.
Infinity Pharmaceuticals Inc is primarily present in the United States of America.
Infinity Pharmaceuticals Inc represents values of innovation, excellence, and commitment to improving patients' lives. The company is dedicated to developing groundbreaking treatments for patients with unmet medical needs, particularly in the field of oncology. Infinity Pharmaceuticals Inc's corporate philosophy revolves around leveraging their expertise in drug discovery and development to advance novel therapies and deliver value to patients, healthcare providers, and stakeholders. By consistently pursuing scientific excellence, translating innovative ideas into potential therapies, and maintaining strategic collaborations, Infinity Pharmaceuticals Inc strives to make a meaningful impact on patients' lives and contribute to the advancement of cancer treatment options.
8 analysts currently rate the Infinity Pharmaceuticals stock: 0 recommend buying, 3 holding and 5 selling.
Converted at the current exchange rate, the Infinity Pharmaceuticals share trades at 0.00 EUR (0.00 USD).
The Infinity Pharmaceuticals share (INFIQ) is listed on 4 stock exchanges, including: NASDAQ (INFI), Frankfurt (I3F.F), München (I3F.MU), Düsseldorf (I3F.DU).
The business model of Infinity Pharmaceuticals is focused on developing innovative drug candidates for cancer treatment and testing them in various phases of clinical trials. The company focuses on drugs that target the proliferative signaling cascade of cancer cells in novel ways in order to selectively kill tumor cells. The company also collaborates with other pharmaceutical companies to accelerate the development of new drugs. Infinity Pharmaceuticals has a diverse pipeline of promising drug candidates, with IPI-549 being one of the most advanced drugs currently being tested in Phase 2 studies for the treatment of various types of cancer such as melanoma and breast cancer. Another promising drug, IPI-582, is currently in Phase 1 studies for the treatment of different types of cancer and has the potential to effectively inhibit tumor invasion and metastasis. In addition to its development and commercialization strategy, Infinity Pharmaceuticals conducts extensive research activities to identify new target molecules that play a role in the treatment of cancer. The success of Infinity Pharmaceuticals' business model is ensured by the company's strong commitment to researching and developing innovative cancer therapies. The extensive product pipeline and collaborations with other companies also provide a solid foundation for future growth. In conclusion, the business model of Infinity Pharmaceuticals is focused on developing innovative drug candidates for cancer treatment and testing them in various phases of clinical trials. The company aims to provide better chances of survival and improved quality of life for cancer patients.
The revenue cannot currently be calculated for Infinity Pharmaceuticals.
The profit cannot currently be calculated for Infinity Pharmaceuticals.
The P/E ratio cannot be calculated for Infinity Pharmaceuticals at the moment.
The P/S cannot be calculated for Infinity Pharmaceuticals currently.
The Eulerpool Quality Score for Infinity Pharmaceuticals is 2/10.
The ISIN of Infinity Pharmaceuticals is US45665G3039. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Infinity Pharmaceuticals is A0LA4Y. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Infinity Pharmaceuticals is INFIQ. The ticker symbol is used to trade Infinity Pharmaceuticals shares on the stock exchange.
Infinity Pharmaceuticals paid dividends every year for the past 0 years.
Infinity Pharmaceuticals is assigned to the 'Health' sector.
The dividends of Infinity Pharmaceuticals are distributed in USD.
Infinity Pharmaceuticals stock
Infinity Pharmaceuticals Peer Group
Infinity Pharmaceuticals Ticker
Infinity Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Infinity Pharmaceuticals
Our stock analysis for Infinity Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Infinity Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.